Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patent Watch
  • Published:

Patent watch

Nature Reviews Drug Discovery volume 12, pages 14–15 (2013)Cite this article

Subjects

One drug hit particularly hard by patent expiry is the statin Lipitor, which is used to treat high cholesterol levels. Worldwide sales of Lipitor in the third quarter of 2012 were $749 million, compared to $2.6 billion in the same period of 2011 — a drop of 71% (see Table 1 for drugs with large revenue losses). The loss of patent protection meant that worldwide sales of generic atorvastatin had reached $1.7 billion in the first 6 months of 2012 (Ref. 2).

Table 1 Drugs with large revenue losses in 2011–2012
Full size table

The impact of the patent cliff over the 2011–2012 period has also been notable in the psychiatry sector. According to Charlotte Mackey, a lead analyst at Datamonitor: “Four atypical antipsychotic drugs — Zyprexa (olanzapine), Seroquel, Geodon (ziprasidone) and Invega (paliperidone) — have lost US patent protection over this time frame.”

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Worldwide sales at risk from patent expiration (2004–2018).

References

  1. EvaluatePharma. World Preview 2018 — Embracing the patent cliff. EvaluatePharma website [online], (2012).

  2. Palmer, E. Top 20 generic molecules worldwide. FiercePharma website [online], (2012).

  3. IMS Institute for Healthcare Informatics. The global use of medicines: outlook through 2016. IMS Health website [online], (2012).

  4. Medtrack. Medtrack Patent Report — 2013 expiring patents. (2011).

Download references

Authors
  1. Charlotte Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, C. Patent watch. Nat Rev Drug Discov 12, 14–15 (2013). https://doi.org/10.1038/nrd3924

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3924

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing